T. Rowe Price Associates, Inc. filed Amendment No. 8 to its Schedule 13G with the SEC on November 16, 2026, disclosing its beneficial ownership position in Monte Rosa Therapeutics Inc. as of the event date of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Associates, Inc. reported beneficially owning 7,356,865 shares of Monte Rosa Therapeutics Inc. common stock.
  • Percent of class: The reported holdings represent 8.6% of the class of securities.
  • Sole voting power: T. Rowe Price Associates reported sole voting power over 7,349,108 shares.
  • Sole dispositive power: The filer reported sole dispositive power over 7,356,865 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Triggering event date: The date of event requiring this filing is stated as September 30, 2026.

T. Rowe Price Discloses 8.6% Stake in Monte Rosa Therapeutics

According to the filing, T. Rowe Price Associates, Inc., a Maryland-incorporated investment adviser, submitted Amendment No. 8 to Schedule 13G regarding its holdings in Monte Rosa Therapeutics Inc. (NASDAQ:GLUE), whose principal executive offices are listed at 645 Summer Street, Suite 102, Boston, MA, 02210. The CUSIP number for the common stock covered by this filing is 61225M102.

The filing discloses that as of September 30, 2026, T. Rowe Price Associates held an aggregate beneficial ownership of 7,356,865 shares, representing 8.6% of the class. Of those shares, 7,349,108 are subject to sole voting power, while 7,356,865 are subject to sole dispositive power. The filing reports no shared voting power and no shared dispositive power. T. Rowe Price Associates is identified as an investment adviser (type "IA") and is organized under the laws of Maryland, with its principal business office at 1307 Point Street, Baltimore, MD 21231.

The filing includes a certification by T. Rowe Price Associates stating that the referenced securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing was signed by Ellen York, Vice President of T. Rowe Price Associates, Inc., on November 16, 2026. The filing also states that "the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."

What Was Disclosed

T. Rowe Price Associates, Inc. disclosed, via Amendment No. 8 to Schedule 13G, beneficial ownership of 7,356,865 shares of Monte Rosa Therapeutics Inc. common stock, equal to 8.6% of the class, as of September 30, 2026, with all voting and dispositive power held solely.